XBIO
XBIO
NASDAQ · Biotechnology

Xenetic Biosciences Inc

$2.85
-0.10 (-3.23%)
Financial Highlights (FY 2026)
Revenue
3.84M
Net Income
-3,456,416
Gross Margin
97.9%
Profit Margin
-90.1%
Rev Growth
+20.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 97.9% 97.9% 44.0% 44.0%
Operating Margin -95.2% -85.7% -30.8% -29.4%
Profit Margin -90.1% -85.6% -29.9% -25.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.84M 3.19M 899.1K 945.5K
Gross Profit 3.76M 3.12M 395.9K 416.3K
Operating Income -3,654,440 -2,734,222 -277,010 -277,924
Net Income -3,456,416 -2,586,062 -268,437 -236,795
Gross Margin 97.9% 97.9% 44.0% 44.0%
Operating Margin -95.2% -85.7% -30.8% -29.4%
Profit Margin -90.1% -85.6% -29.9% -25.1%
Rev Growth +20.3% +20.3% -1.1% +22.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 814.0K 797.5K
Total Equity 2.89M 2.95M
D/E Ratio 0.28 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -3,654,741 -2,886,361 -429,552 -415,366
Free Cash Flow -251,567 -250,593